Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...
Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...
Hosted on MSN2d
Drugmakers Just Hiked Prices for Over 500 MedicinesPharmaceutical companies just raised list prices for over 500 medicines, including Novo Nordisk’s Ozempic, Gilead’s HIV-1 ...
Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...
San Francisco and its hotel industry are partnering to beef up security around this week's 43rd annual J.P. Morgan Healthcare ...
Michael Yee, an analyst from Jefferies, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...
FAYETTEVILLE, NY, UNITED STATES, January 10, 2025 /EINPresswire / -- Additional January 2025 Prescription Drug Price Changes Show Further ...
Addressing stigma, inequity, and access to HIV innovations remains critical to progress in the global HIV response, says IAS ...
The list prices of the top 25 drugs with the highest Medicare Part D spend that are not subject to drug price negotiations ...
Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like ...
The changes will result in one company focused exclusively on cancer cell therapies and another on strategic transactions to build a pipeline of innovative medicines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback